Holen Sie sich die Stockscreener-App
0.2101
90.83%
-2.0799
Handel nachbörslich:
.23
0.0199
+9.47%
Schlusskurs vom Vortag:
$2.29
Offen:
$0.3444
24-Stunden-Volumen:
64.03M
Relative Volume:
8.86
Marktkapitalisierung:
$15.20M
Einnahmen:
Nettoeinkommen (Verlust:
$-113.28M
KGV:
-0.1132
EPS:
-1.8557
Netto-Cashflow:
$-105.55M
1W Leistung:
-89.39%
1M Leistung:
-90.54%
6M Leistung:
-91.21%
1J Leistung:
-90.54%
1-Tages-Spanne:
$0.2092
$0.352
1-Wochen-Bereich:
$0.2092
$2.52
52-Wochen-Spanne:
$0.2092
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
617-344-4190
Adresse
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
0.2101 | 15.20M | 0 | -113.28M | -105.55M | -1.8557 |
VRTX
Vertex Pharmaceuticals Inc
|
558.88 | 141.65B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
927.89 | 95.53B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
221.72 | 88.52B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
892.87 | 56.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.33 | 41.89B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Form S-3 Acumen Pharmaceuticals Inc For: 27 October By Investing.com - Investing.com India
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript - The Motley Fool
Acumen Pharmaceuticals (ABOS) Climbs 12.15% to $1.99, Pressing Toward $2.09 ResistanceWeak Sell Signals - https://www.dars.gov.et/
A company developing Alzheimer’s treatments will discuss third-quarter results live on Oct. 26. - Stock Titan
Eledon Pharmaceuticals, Inc. (ELDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Eledon Pharmaceuticals, Inc. (ELDN) stock price, news, quote and history - Yahoo Finance UK
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day - Yahoo Finance
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - PR Newswire
Acumen Pharmaceuticals (NASDAQ: ABOS) Aims for Late 2026 Sabirnetug Phase 2 Topline Data - Kalkine Media
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 - PR Newswire
Form 8K Acumen Pharmaceuticals Inc For: 16 September By Investing.com - Investing.com Nigeria
Form 8K Acumen Pharmaceuticals Inc For: 16 September By Investing.com - Investing.com Canada
Form 8K Acumen Pharmaceuticals Inc For: 16 September By Investing.com - Investing.com UK
BioStem Technologies, Inc. (BSEM) Stock Price & News - Syfe
Acumen will meet investors online Sept. 16 - Stock Titan
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 - Moomoo
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - Moomoo
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
An Alzheimer’s drug developer will join two live online events Sept. 9 and 10 - Stock Titan
PLX Stock Price, Quote & News - Syfe
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026 - Barchart.com
Acumen Pharmaceuticals Earnings Call: Science vs. Runway - TipRanks
Canadian (CSIQ) Update: Rises 2.31% to $15.08 in the Current Update; Market Levels: the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateAnalyst Downgrade Signals - www.dars.gov.et
Acumen Pharmaceuticals Inc (ABOS) Stock News Today - TradingKey
Acumen Pharmaceuticals (ABOS) Advances 4.7% to $2.67 as Momentum BuildsForce Index - vinanet.vn
Acumen Pharmaceuticals (ABOS) Advances 4.7% to $2.67 as Momentum BuildsFundamental Weighted - dars.gov.et
Acumen Pharmaceuticals (ABOS) Advances 4.7% to $2.67 as Momentum BuildsDelta Hedging - dars.gov.et
Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026 - TradingKey
Acumen Pharmaceuticals (ABOS) Edges Higher: Biotech Stock Gains 1.59% as Bulls Target $2.68 ResistanceCall Wall - vinanet.vn
Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4 - moomoo.com
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Acumen Pharmaceuticals Q2 EPS $(0.45) misses $(0.34) estimate - scanx.trade
Acumen Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ABOS) 2026-08-12 - Seeking Alpha
ABOS: Phase II Alzheimer's trial on track for late 2026 readout; strong cash position supports pipeline - TradingView
Acumen Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Acumen Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
ABOS: Phase II Alzheimer's trial on track for late 2026 readout; strong cash position and pipeline progress - TradingView
Second quarter earnings and operational progress released by Acumen Pharmaceuticals, Inc. - Traders Union
Acumen Pharmaceuticals Reports Q2 Results, Advances Alzheimer’s Programs - TipRanks
Form 8K Acumen Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com Australia
Acumen Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Form 8K Acumen Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com India
Form 8K Acumen Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com Canada
Acumen Pharmaceuticals Reports Second-Quarter 2026 Results and Advances Alzheimer’s Pipeline, with ALTITUDE-AD Topline Data Expected in Late 2026 - Quiver Quantitative
Acumen Pharmaceuticals Q2 net loss widens, misses analyst estimates - TradingView
Acumen Reports Q2 Net Loss as Alzheimer’s Trial Readout Nears - Quiver Quantitative
Acumen Pharmaceuticals Reports Second-Quarter 2026 Results and Advances Alzheimer’s Pipeline, with ALTITUDE-AD Topline Data Expected in Late 2026 - Quiver Quantitative
Form 8K Acumen Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com UK
Earnings call transcript: Acumen misses Q2 2026 EPS view as shares slip premarket - Investing.com
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acumen Pharmaceuticals Inc-Aktie (ABOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Porter Derrell | Director |
Jun 17 '26 |
Sale |
2.33 |
13,040 |
30,318 |
35,500 |
| DERRELL PORTER | Director |
Jun 17 '26 |
Proposed Sale |
2.33 |
13,040 |
30,323 |
0 |
| DERRELL PORTER | Director |
Jun 16 '26 |
Proposed Sale |
2.33 |
12,800 |
29,768 |
0 |
| Porter Derrell | Director |
Jun 16 '26 |
Sale |
2.33 |
12,800 |
29,773 |
35,500 |
| Porter Derrell | Director |
Jun 15 '26 |
Option Exercise |
1.07 |
6,460 |
6,912 |
54,760 |
| DERRELL PORTER | Director |
Jun 15 '26 |
Proposed Sale |
2.35 |
6,460 |
15,149 |
0 |
| Porter Derrell | Director |
Jun 15 '26 |
Sale |
2.35 |
6,460 |
15,149 |
48,300 |
| NATHAN FOUNTAIN | Director |
Jun 09 '26 |
Proposed Sale |
2.23 |
6,400 |
14,273 |
0 |
| Fountain Nathan B | Director |
Jun 09 '26 |
Sale |
2.23 |
6,400 |
14,273 |
48,150 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Mar 06 '26 |
Sale |
3.26 |
2,090 |
6,813 |
173,999 |
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):